An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer.

Trial Profile

An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs Everolimus (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Feb 2014 Planned End Date changed from 1 May 2013 to 1 Jan 2015 according to ClinicalTrials.gov record.
    • 26 Feb 2013 Planned end date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top